Skip to content
10-Q

Quarterly Report

Pharma-Bio Serv, Inc. PBSV

0001654954-26-005986

← back to feed
Filed
Jun 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Jun 10, 2026 22.9M sh
Shares Diluted Q2 2026 · Apr 30, 2026 22.91M sh
Shares Diluted Q2 2026 · Apr 30, 2026 22.91M sh
Shares Diluted Q2 2026 · Apr 30, 2025 22.94M sh
Shares Diluted Q2 2026 · Apr 30, 2025 22.95M sh
Stock Repurchased Q2 2026 · Apr 30, 2026 $709
Stock Repurchased Q2 2026 · Apr 30, 2026 $2.39K
Stock Repurchased Q2 2026 · Apr 30, 2025 $17.24K
Stock Repurchased Q2 2026 · Apr 30, 2025 $17.24K
Dividends Paid Q2 2026 · Apr 30, 2026 $1.72M
Dividends Paid Q2 2026 · Apr 30, 2026 $1.72M
Dividends Paid Q2 2026 · Apr 30, 2025 $1.72M
Dividends Paid Q2 2026 · Apr 30, 2025 $1.72M
Dividends Paid restated Q2 2026 · Jan 28, 2025 $1.72M
Capex Q2 2026 · Apr 30, 2026 $2.32K
Capex Q2 2026 · Apr 30, 2026 $4.73K
Capex Q2 2026 · Apr 30, 2025 $4.26K
Capex Q2 2026 · Apr 30, 2025 $4.26K
Operating Cash Flow Q2 2026 · Apr 30, 2026 −$365.31K
Operating Cash Flow Q2 2026 · Apr 30, 2026 −$755.45K
Operating Cash Flow Q2 2026 · Apr 30, 2025 −$301.59K
Operating Cash Flow Q2 2026 · Apr 30, 2025 −$731.08K
Stockholders Equity Q2 2026 · Apr 30, 2026 $10.45M
Stockholders Equity Q2 2026 · Jan 31, 2026 $10.24M
Stockholders Equity Q2 2026 · Oct 31, 2025 $11.91M
Stockholders Equity Q2 2026 · Apr 30, 2025 $12.12M
Stockholders Equity Q2 2026 · Jan 31, 2025 $12M
Stockholders Equity Q2 2026 · Oct 31, 2024 $13.72M
Current Liabilities Q2 2026 · Apr 30, 2026 $1.05M
Current Liabilities Q2 2026 · Oct 31, 2025 $1.74M
Total Liabilities Q2 2026 · Apr 30, 2026 $1.05M
Total Liabilities Q2 2026 · Oct 31, 2025 $1.74M
Current Assets Q2 2026 · Apr 30, 2026 $11.29M
Current Assets Q2 2026 · Oct 31, 2025 $13.39M
Total Assets Q2 2026 · Apr 30, 2026 $11.5M
Total Assets Q2 2026 · Oct 31, 2025 $13.65M
Eps Diluted Q2 2026 · Apr 30, 2026 $0.01
Eps Diluted Q2 2026 · Apr 30, 2026 $0.01
Eps Diluted Q2 2026 · Apr 30, 2025 $0.00
Eps Diluted Q2 2026 · Apr 30, 2025 $0.01
Sga Expense Q2 2026 · Apr 30, 2026 $757.37K
Sga Expense Q2 2026 · Apr 30, 2026 $1.57M
Sga Expense Q2 2026 · Apr 30, 2025 $917.05K
Sga Expense Q2 2026 · Apr 30, 2025 $1.78M
Net Income Q2 2026 · Apr 30, 2026 $232.99K
Net Income Q2 2026 · Apr 30, 2026 $265.85K
Net Income Q2 2026 · Apr 30, 2025 $95.35K
Net Income Q2 2026 · Apr 30, 2025 $103.89K
Operating Income Q2 2026 · Apr 30, 2026 $144.68K
Operating Income Q2 2026 · Apr 30, 2026 $50.14K
Operating Income Q2 2026 · Apr 30, 2025 −$98.32K
Operating Income Q2 2026 · Apr 30, 2025 −$190.51K
Gross Profit Q2 2026 · Apr 30, 2026 $902.04K
Gross Profit Q2 2026 · Apr 30, 2026 $1.62M
Gross Profit Q2 2026 · Apr 30, 2025 $818.73K
Gross Profit Q2 2026 · Apr 30, 2025 $1.59M
Cost Of Revenue Q2 2026 · Apr 30, 2026 $1.8M
Cost Of Revenue Q2 2026 · Apr 30, 2026 $3.37M
Cost Of Revenue Q2 2026 · Apr 30, 2025 $1.6M
Cost Of Revenue Q2 2026 · Apr 30, 2025 $3.3M
Revenue Q2 2026 · Apr 30, 2026 $2.7M
Revenue Q2 2026 · Apr 30, 2026 $5M
Revenue Q2 2026 · Apr 30, 2025 $2.42M
Revenue Q2 2026 · Apr 30, 2025 $4.89M